SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-068757
Filing Date
2022-03-08
Accepted
2022-03-08 08:26:02
Documents
14
Period of Report
2022-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d682941d8k.htm   iXBRL 8-K 23912
2 EX-99.1 d682941dex991.htm EX-99.1 46080
6 GRAPHIC g682941assdff.jpg GRAPHIC 3277
  Complete submission text file 0001193125-22-068757.txt   205183

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mgta-20220308.xsd EX-101.SCH 2862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20220308_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20220308_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d682941d8k_htm.xml XML 3341
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 22720399
SIC: 2834 Pharmaceutical Preparations